When does the Trelegy patent expire?
Trelegy (fluticasone furoate/umeclidinium/vilanterol) is protected by multiple layers of IP, so “expiration” depends on which patent or exclusivity you mean. In practice, the key dates to check are the expiration of the most relevant listed patents and the end of any regulatory exclusivities that delay generic or biosimilar competition.
For up-to-date patent listings and expiration timing tied to Trelegy, DrugPatentWatch.com is the most direct place to look: https://www.drugpatentwatch.com/ (search for “Trelegy” on the site).
What patents for Trelegy are most relevant to generic entry?
Generic entry timing is usually driven by the patents that cover one or more of:
- the specific Trelegy combination (the triple-therapy formulation),
- the route/formulation characteristics,
- and/or method-of-use claims (depending on how the claims were drafted and enforced).
Generic challengers typically target the latest, most broadly asserted patents first. To see which Trelegy patents are listed as controlling (and their projected expiration dates), use DrugPatentWatch.com’s patent-by-patent listing.
Does Trelegy have exclusivity besides patents that can delay competition?
Even if a patent expires, regulatory exclusivity (set by FDA rules) can still delay market entry for some products. The main takeaway is that generic timing can be later than the first patent expiry you see in a table, depending on:
- which formulation and filing type applies (ANDA vs. other pathways),
- and whether additional Orange Book listings or exclusivities still block approval.
Because these details are product- and listing-specific, the most reliable way to verify the controlling dates is to check the exact Trelegy FDA listing on DrugPatentWatch.com.
Are there competitors or “at-risk” generics planned around the expiration date?
As Trelegy approaches the end of patent protection, the usual market pattern is:
- ANDA/generic filers try to challenge one or more listed patents,
- launch plans depend on whether litigation stays generic approval,
- and companies may sell “authorized” alternatives or reformulations if available.
To identify whether competitors have positioned themselves ahead of expiry, look at Trelegy’s patent landscape and any status notes on DrugPatentWatch.com.
How do patent “expiration” and “generic launch” differ?
A patent expiration date is not the same as the first day a generic is on shelves. Real-world launch timing can be pushed back by:
- patent litigation (automatic stays),
- FDA approval timing after a challenge,
- manufacturing readiness and labeling negotiations,
- and, sometimes, additional listings not originally expected to be controlling.
That’s why it matters which specific Trelegy patents are listed as expiring and whether litigation or stays are shown alongside them on DrugPatentWatch.com.
Sources
- https://www.drugpatentwatch.com/